FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C. 2054	9
-------------	-----------	---

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Instruction 1(b).	pursuant to Section 16(a) of the Securities Exchange Act of 1934								
	or Section 30(h) of the Investment Company Act of 1940								
1. Name and Address of Reporting Person* Bolzon Bradley J PhD	2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX ]	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner     Officer (give title Other (specify							
(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC 139 MAIN STREET	3. Date of Earliest Transaction (Month/Day/Year) 11/11/2020	below) below)							
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person							

CAMBRIDGE MA						'	•	More than One		
(City) (State)	(Zip)							. 2.30		
	Table I - Non-Deriva	tive Securities	s Acqu	irec	d, Dispose	ed of,	or Beneficia	lly Owned		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquire (D) (Inst	ed (A) or tr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	11/11/2020		<b>J</b> <sup>(1)</sup>		690,814	D	\$0.00	4,955,563	I	See Footnote <sup>(2)</sup>
Common Stock	11/11/2020		J <sup>(3)</sup>		13,816	A	\$0.00	13,816	I	See Footnote <sup>(4)</sup>
Common Stock	11/11/2020		J <sup>(5)</sup>		13,816	D	\$0.00	0	I	See Footnote <sup>(4)</sup>
Common Stock	11/11/2020		J <sup>(6)</sup>		11,918	A	\$0.00	11,918	I	See Footnote <sup>(7)</sup>
Common Stock	11/11/2020		J <sup>(8)</sup>		11,918	D	\$0.00	0	I	See Footnote <sup>(7)</sup>
Common Stock	11/11/2020		J <sup>(9)</sup>		3,954	A	\$0.00	14,132	D	
Common Stock	11/11/2020		J <sup>(10)</sup>		199,652	D	\$0.00	1,432,212	I	See Footnote <sup>(11</sup>
Common Stock	11/11/2020		J <sup>(12)</sup>		1,071	A	\$0.00	1,071	I	See Footnote <sup>(13)</sup>
Common Stock	11/11/2020		J <sup>(14)</sup>		59,534	D	\$0.00	427,063	I	See Footnote <sup>(1)</sup>
Common Stock	11/11/2020		J <sup>(16)</sup>		3,211	A	\$0.00	4,282	I	See Footnote <sup>(13)</sup>
Common Stock	11/11/2020		J <sup>(17)</sup>		4,282	D	\$0.00	0	I	See Footnote <sup>(1)</sup>
Common Stock	11/11/2020		J <sup>(18)</sup>		1,502	A	\$0.00	15,634	D	
Common Stock	11/12/2020		S <sup>(19)</sup>		524	D	\$33.4774(20)	986,512	I	See Footnote <sup>(21)</sup>
Common Stock	11/12/2020		S <sup>(19)</sup>		1,248	D	\$34.3928(22)	985,264	I	See Footnote <sup>(2)</sup>
Common Stock	11/12/2020		S <sup>(19)</sup>		47	D	\$35.1488(23)	985,217	I	See Footnote <sup>(2)</sup>
Common Stock	11/12/2020		<b>S</b> <sup>(19)</sup>		3,976	D	\$33.4774(20)	4,951,587	I	See Footnote <sup>(2)</sup>
Common Stock	11/12/2020		S <sup>(19)</sup>		9,450	D	\$34.3928(22)	4,942,137	I	See Footnote <sup>(2)</sup>
Common Stock	11/12/2020		S <sup>(19)</sup>		353	D	<b>\$</b> 35.1488 <sup>(23)</sup>	4,941,784	I	See Footnote <sup>(2)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3) 1. Title of Conversion or Exercise Price of Derivative	(Month/Day/Year)  3. Transaction Date	A Pep Derivat Execution Date, if any (e.g., pt (Month/Bay/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)	iransa ItSo,dG	action Ales, V	Of VENTION Sect Acqui (SA)No Disp Dis(E) (Sast		Expiration Da Opplicants y/O 6. Date Exerc Expiration Da (Month/Day/Y	isable and	S & C	int of Charlet in the	Perivative	99. Number of derivative Securities Beneficially Owned Following of Repivation Semination (s) Besterically Owned	10. Ownership Form: Direct (D) or Indirect (ID) (Instr. 4) Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Security  Explanation of Respon			Code	v	of (D	sed r. 3, 4	Date Exercisable	Expiration Date		ity (Instr. 4)Amount or Number of Shares Amount		Following Reported Transaction(s) (Instr. 4)	(I) (Instr. 4)	

- 1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Expiration, L.P. ("Versant VI"), to its partners.

  2. Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 3. Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no
- 4. Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary
- 5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners.
- 6. Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP.
- 7. Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VI GP-GP, however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 8. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members
- 9. Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP-GP.
- 10. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I"), to its partners.
- 11. Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 12. Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I.
- 13. Shares held by Versant Voyageurs I GP LP. The Reporting Person is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP: however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 14. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), to its partners.
- 15. Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 16. Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel.
- 17. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners.
- 18. Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I GP LP.
- 19. The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant VI, respectively.
- 20. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.00 to \$33.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (20) to this Form 4.
- 21. Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP-LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 22. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.00 to \$34.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (22) to this Form 4.
- 23. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.00 to \$35.545, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (23) to this Form 4.

## Remarks:

/s/ Robin L. Praeger, Attorney - in - fact for Bradley J. 11/13/2020 Bolzon, PhD.

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.